European Patent Office

T 2591/18 (Pharmaceutical compsitions comprising nilotinib/NOVARTIS) of 25.01.2022

European Case Law Identifier
ECLI:EP:BA:2022:T259118.20220125
Date of decision
25 January 2022
Case number
T 2591/18
Petition for review of
-
Application number
07820560.6
Language of proceedings
English
Distribution
No distribution (D)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB OR ITS SALT
Applicant name
Novartis AG
Opponent name
Generics [UK] Limited
Strawman Limited
Fresenius Kabi Deutschland GmbH
medac Gesellschaft für klinischeSpezialpräparate mbH
Board
3.3.07
Headnote
-
Relevant legal provisions
European Patent Convention Art 123(2)European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 013(2)
Keywords
Amendments - allowable (yes)
Admission of arguments on inventive step (Yes)
Main request - Inventive step (Yes)
Catchword
-
Cited cases
T 0247/20
Citing cases
T 2623/18T 0072/23

Order

For these reasons it is decided that:

The appeals are dismissed.